A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM). - Trial 2021-001087-24

Name: Clinical Trial 2021-001087-24
Creator: Danish Headache Center
Keywords: Migraine, clinical trial

Access comprehensive clinical trial information for 2021-001087-24 through Pure Global AI's free database. This phase not specified trial is sponsored by Danish Headache Center and is currently status unknown. The study focuses on Migraine.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2021-001087-24

Trial Details

EU Clinical Trials Register • 2021-001087-24

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).

Study Focus

Disease/Condition

Migraine

Sponsor & Location

Primary Sponsor

Danish Headache Center

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

ICD-10 Classifications

Migraine

Other migraine

Migraine, unspecified

Complicated migraine

Headache

Data Source

Registry

EU Clinical Trials Register

Trial ID

2021-001087-24

Type

Non-Device Trial